APA

APA 2024: Case report describes suicidal ideation in semaglutide recipient

May 9, 2024

A 42-year-old female who exhibited suicidal ideation after starting semaglutide was the subject of this case study, presented on May 4, 2024, at the American Psychiatric Association’s Annual Meeting. Researchers examined extant literature, which uncovered numerous studies illuminating the complications associated with GLP-1 medication in patients with psychiatric disorders.

• Researchers uncovered approximately 60 documented cases of suicidal ideation and 7 suicide attempts since 2018.
• Many of these patients, including the subject here, reported significantly improved depression post-discontinuation, suggesting that semaglutide therapy may induce a psychiatric adverse effect of depression in select patients. However, the precise mechanism remains elusive.
• These findings necessitate further research to identify the specific proteins and enzymes implicated in exacerbating current psychiatric conditions and triggering suicidal ideation.

Source:

Kakarlapudi R, et al. Semaglutide-induced suicidal ideation in a patient with psychiatric comorbidities: a case report: Poster P03-006. Presented at: American Psychiatric Association 2024 Annual Meeting; May 4-8, 2024; New York City, NY. https://s7.goeshow.com/apa/annual/2024/poster_search.cfm?session_key=8E8DFE6F-90B1-1C06-DFD2-CA2230FD8375&session_date=Saturday,%20May%2004,%202024